Information Provided By:
Fly News Breaks for July 25, 2019
GNCA
Jul 25, 2019 | 12:37 EDT
H.C. Wainwright analyst Joseph Pantginis lowered his price target on Genocea shares to $32 from $42 to reflect the recent dilution from the company's equity raise, but he keeps a Buy rating on the stock as he believes the company has "set an exciting agenda for the remaining of the year." Genocea showed "encouraging data" on the company's neoantigen platform ATLAS at both the SITC meeting in November 2018 and at AACR in March 2019, Pantginis said.